Dexone (Canada)

This page contains information on Dexone for veterinary use.
The information provided typically includes the following:
  • Dexone Indications
  • Warnings and cautions for Dexone
  • Direction and dosage information for Dexone

Dexone

This treatment applies to the following species:
Manufacturer: Jaapharm

Dexamethasone Powder

DIN 00786012

DESCRIPTION:

First oral corticosteroid for large animals.

Each 15 g packet of Dexone Powder contains:

Crystalline dexamethasone

10 mg

INDICATIONS:

CATTLE AND HORSES - The use of Dexone Powder is recommended as primary therapy for the treatment of arthritis and inflammatory conditions involving the joints and accessory structures. For supportive therapy, this dosage form is indicated in pneumonia, rhinitis and other respiratory conditions, osteoarthritic lameness and various stress conditions in cattle and horses such as ketosis and metritis, dystocias and retained placenta in cattle, and traumatic injuries to the appendicular skeleton in horses.

CAMELS - The use of Dexone Powder is recommended as primary therapy for the treatment of arthritis and inflammatory conditions involving the joints and accessory structures, respiratory conditions and various stress conditions.

ACTION:

Dexone possesses unsurpassed anti-inflammatory, anti-allergic and anti-stress activity. Experimental and clinical studies have demonstrated that Dexone has an anti-inflammatory activity approximately 20 times that of prednisone and 70 to 80 times that of hydrocortisone. Effective maintenance doses apparently do not cause sodium and fluid retention or potassium loss; there is not concomitant increase in undesirable effects. Continuous large doses of Dexone may result in some depression of adrenocorticoid function and may produce adrenal atrophy. Therefore, it may be advisable to institute rest periods and to stimulate adrenocortical function by the use of ACTH. With exceedingly high dosages, metabolic studies indicate that animals exhibit nitrogen losses on controlled and limited protein intake.

ADVANTAGES:

Dexone Powder represents the first oral corticosteroid dosage forms developed expressly for large animal use. Because Dexone exhibits a greatly enhanced anti-inflammatory effect in the treatment of corticosteroid-responsive conditions, therapeutically effective dosages as low as 1/20 those of the injectable prednisteroids may be administered. In most cases, 5 to 10 mg of Dexone is sufficient to elicit the desired response. Greater economy in the treatment of large animals is afforded by the low dosages required and the comparative low cost of Dexone in powder form. Dexone Powder is an excellent dispensing item and provides the client with a convenient method of follow-up therapy. The powder has proved particularly beneficial in horse practice.

DOSAGE:

The dosage of Dexone must be individualized according to the severity of the condition, anticipated duration of therapy, tolerance to the steroid and the response obtained. Dexone Powder is easily administered by drench or by sprinkling on a small amount of feed. Treatment may be changed to Dexone from any of the older corticosteroids with the proper reduction of dosage. Recommended dosages should not be exceeded.

CATTLE - 5 to 10 mg 1st day, then 5 mg daily is required. If treatment is initiated with Dexone solution maintenance therapy may be given orally 24 to 48 hours later with 5 mg of Dexone Powder, treatment may be repeated as necessary.

HORSES - 5 to 10 mg daily in single or divided doses until a clinical response is noted.

If a response to Dexone is not achieved in five days, the possibility should be considered that the condition under treatment is not amenable to corticosteroid therapy and other therapy should be initiated. The use of oral Dexone is supportive therapy in animals with acute or chronic bacterial infections does not eliminate the need to employ specific antibiotic or chemotherapeutic agents to combat the primary condition. All corticosteroids may mask signs of infection, therefore, if questionable findings occur, temporarily discontinue therapy with this product until a definite diagnosis is made.

CAMELS - 10 to 20 mg daily in single or divided doses until a clinical response is noted.

If response to Dexone is not achieved in five days, the possibility should be considered that the condition under treatment is not amenable to corticosteroid therapy and other therapy should be initiated. The use of oral Dexone is supportive therapy in animals with acute or chronic bacterial infections does not eliminate the need to employ specific antibiotic or chemotherapeutic agents to combat the primary condition. All corticosteroids may mask signs of infection, therefore, if questionable findings occur, temporarily discontinue therapy with this product until a definite diagnosis is made.

CAUTION:

Because Dexone is an extremely potent drug with profound physiological effects, all precautions and contraindications for adrenocortical hormones must be observed. The warning signs of cortisone overdosage may not be present with Dexone therapy. In certain cases where large doses are required, the patient must be closely observed for side effects such as polyuria and polydipsia. When side effects occur, it may be necessary to reduce the dosage or to discontinue therapy. Continuous large doses of Dexone may result in some depression of adrenocortical function and may produce adrenal atrophy. Rest periods and stimulation of adrenocortical function with ACTH may be advisable. If long-term Dexone therapy is to be terminated, gradual withdrawal is recommended. Should the animal subsequently be subjected to shock or undue stress, temporary therapy with dexamethasone is recommended. The possible action of Dexone in delaying wound healing also should be considered.

Presentation:

10 sachets/box

NAC No.: 12260210

JAAPHARM CANADA INC.
510 ROWNTREE DAIRY ROAD, BUILDING "J", WOODBRIDGE, ON, L4L 8H2
Telephone:   905-851-7885
Order Desk:   800-465-9587
Toll-Free Fax:   888-606-4777
Fax:   905-856-5838
Website:   www.jaapharm.com
Email:   info@jaapharm.com
Every effort has been made to ensure the accuracy of the Dexone information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-07-28

(web4)